Motley Fool Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.17M | Buy |
6,652
+623
| +10% | +$203K | 0.1% | 148 |
|
|
2025
Q1 | $1.63M | Buy |
6,029
+4,130
| +217% | +$1.12M | 0.09% | 151 |
|
|
2024
Q4 | $447K | Buy |
1,899
+139
| +8% | +$32.7K | 0.02% | 178 |
|
|
2024
Q3 | $486K | Sell |
1,760
-130
| -7% | -$35.9K | 0.03% | 165 |
|
|
2024
Q2 | $460K | Sell |
1,890
-70
| -4% | -$17K | 0.03% | 167 |
|
|
2024
Q1 | $293K | Sell |
1,960
-75
| -4% | -$11.2K | 0.02% | 199 |
|
|
2023
Q4 | $390K | Sell |
2,035
-196
| -9% | -$37.5K | 0.03% | 181 |
|
|
2023
Q3 | $395K | Sell |
2,231
-48
| -2% | -$8.5K | 0.03% | 181 |
|
|
2023
Q2 | $433K | Buy |
+2,279
| New | +$433K | 0.04% | 172 |
|
|
2023
Q1 | – | Sell |
-2,181
| Closed | -$518K | – | 115 |
|
|
2022
Q4 | $518K | Sell |
2,181
-198
| -8% | -$47.1K | 0.06% | 162 |
|
|
2022
Q3 | $476K | Sell |
2,379
-54
| -2% | -$10.8K | 0.05% | 170 |
|
|
2022
Q2 | $367K | Buy |
2,433
+9
| +0.4% | +$1.36K | 0.03% | 181 |
|
|
2022
Q1 | $396K | Buy |
2,424
+2,368
| +4,229% | +$387K | 0.03% | 175 |
|
|
2021
Q4 | $9K | Buy |
+56
| New | +$9K | ﹤0.01% | 188 |
|